Related Experiment Video

Updated: Apr 13, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure

Kazuhiko Kido1, Sara D Brouse, Tracy E Macaulay

  • 1University of Kentucky Health Care, 800 Rose Street, H-110, Lexington, KY 40536, USA. kazuhiko.kido@uky.edu.

Current Drug Safety
|April 30, 2015
PubMed

Insights

Continuing carvedilol therapy significantly lowered ventricular arrhythmia rates in systolic heart failure patients. Dose reduction or discontinuation of carvedilol increased arrhythmia events, with no dose-dependent withdrawal effects observed.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Systolic heart failure (EF < 40%) requires careful management of medication.
  • Carvedilol is a beta-blocker commonly prescribed for heart failure.
  • Ventricular arrhythmias pose a significant risk in heart failure patients.

Purpose of the Study:

  • To evaluate the impact of carvedilol dose adjustments on ventricular arrhythmia rates.
  • To examine dose-dependent effects of carvedilol withdrawal in patients with systolic heart failure.

Main Methods:

  • Retrospective cohort study of adult patients with systolic heart failure on carvedilol.
  • Comparison of ventricular arrhythmia incidence across carvedilol dose continuation, reduction, and discontinuation groups.
  • Subgroup analysis to assess dose-dependent effects of beta-blocker withdrawal.

Main Results:

  • Significantly higher ventricular arrhythmia rates in dose discontinuation (65.6%) and reduction (33.7%) groups compared to the continuation group (15.3%).
  • The dose discontinuation group showed a higher event rate than the dose reduction group (p<0.001).
  • No significant differences in ventricular arrhythmia rates were found among subgroups for dose discontinuation or reduction.

Conclusions:

  • Continuation of carvedilol therapy is associated with substantially lower ventricular arrhythmia event rates.
  • Reducing or discontinuing carvedilol therapy increases the risk of ventricular arrhythmias.
  • No dose-dependent effects of beta-blocker withdrawal were identified in subgroup analyses.
Abstract

More Related Videos

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.9K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.3K

Related Concept Videos

Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
4.5K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
1.1K
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.7K
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
845
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.4K